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ABSTRACT
Intravitreal injections with vascular endothe-
lial growth factor inhibitors constitute the
most prevalent ophthalmic procedure in
developed countries. Historically, there has
been steady growth in the number of treat-
ments performed of this kind, and projection
studies estimate further growth in such treat-
ments in the future. We provide a practical
approach to intravitreal injections and discuss
important aspects relating to the setting, the
patient, the procedure, and the information
given to the patient.
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Key Summary Points
Why carry out this study?
Intravitreal injections (IVIs) with vascular
endothelial growth factor inhibitors
represent the most prevalent ophthalmic
procedure in developed countries.
This paper aims to provide a practical
approach to IVIs.
What was learned from the study?
We describe important aspects relating to
the setting, the patient, the procedure,
and the information given to the patient.
We outline a best practice protocol for the
procedure.
INTRODUCTION
Intravitreal injection (IVI), a means of accessing
the retina for therapeutic purposes, has been
performed for over a century [1, 2]. It gained
considerable popularity in 1970s with the
administration of intravitreal antibiotics and
steroids [2]. Research efforts during the 1990s
elucidated that ocular neovascularization is
related to vascular endothelial growth factor
(VEGF) expression [3, 4]. This finding sparked
an impressive effort to develop VEGF-targeted
therapy, which led to the introduction of VEGF
inhibitors (anti-VEGF) delivered through IVI.
The therapeutic indication was initially neo-
vascular age-related macular degeneration—the
most prevalent cause of irreversible vision loss
in developed countries [5]. Since then, the
therapeutic indication has been extended to a
number of other prevalent retinal diseases, such
as retinal vein occlusion, diabetic macular
edema, and choroidal neovascularization due to
other conditions [6]. Overall, these develop-
ments have dramatically changed the number
of IVIs performed worldwide: according to
records in the American Medical Association
Specialty Society Relative Value Scale Update
Committee database, the number of injections
performed increased more than 500-fold during
the period from 2000 to 2012 (from 4500 to 2.3
million injections per year) [7], and similar
developments have been reported in the United
Kingdom (UK) [8]. Due to population aging in
many developed countries, forecasting studies
on retinal diseases indicate that we should
expect an ever-increasing number of patients
who need this treatment [9–11]. These circum-
stances contribute to the fact that IVIs with
anti-VEGF constitute an important, high-vol-
ume procedure of any ophthalmic service. In
this paper, we provide a practical approach to
IVIs with anti-VEGF. This article is based on
previously conducted studies and does not
contain any studies with human participants or
animals performed by any of the authors.
SETTING
The predominant setting for IVI differs across
countries for reasons that include regulations,
reimbursement considerations, and traditions.
For example, an operating theater with air fil-
tration systems is an official requirement for a
setting in which IVIs are performed according
to Swiss regulations [13]. In Italy, the National
Society of Ophthalmologists guidelines recom-
mend that IVIs should be performed in operat-
ing theaters under sterile conditions [14]. In the
UK and the Netherlands, most clinics adminis-
ter IVIs in a dedicated clean room [15] that has
high hygiene standards but does not have air
filtration systems. Compensation rates for IVIs
can vary by almost a factor of ten across Europe
[13]. In Germany and Denmark, IVIs are
restricted to large public hospitals [13], which
impacts the perceived burden of treatment on
patients from rural areas [16]. There are also
differences in whether there are organizational
incentives to increase or decrease the number of
IVIs (which can be obtained through different
treatment regimens) or the waiting times for
patients [13]. In the Netherlands, there are
marked differences in the IVI procedure across
the country: sterile gloves are worn during the
192 Ophthalmol Ther (2020) 9:191–203
procedure in some hospitals whereas no gloves
are used in other hospitals.
Operating Theater Versus Office
Whether to perform the IVIs in an operating
theater or in an office has been debated. The
theoretical rationale for performing IVIs in
operating theaters is that air filtration systems
can help to remove contaminants from the air
and reduce the risk of infection from airborne
particles [12].
A number of European retrospective studies
have reported the incidence of endophthalmitis
after IVI in operating theaters with laminar
airflows [17–19]. In two Swiss centers, three
cases of endophthalmitis were reported after a
total of 40,011 IVIs (incidence of 0.0075%) [17].
In a Danish center, no cases of endophthalmitis
were reported after 20,293 IVIs [18]. In a mul-
ticenter European study, 10 cases of endoph-
thalmitis were reported after a total of 134,701
IVIs (incidence of 0.0074%) [19]. Studies on the
incidence of endophthalmitis after IVI in an
office setting are mostly based on data from the
United States. A single-center study from New
York reported three cases after 10,254 IVIs (in-
cidence of 0.029%) [20]. Results from the mul-
ticenter Comparison of Age-Related Macular
Degeneration Treatments Trials found 11 cases
after 18,509 IVIs (incidence of 0.059%) [21]. In a
large multicenter study of five retina practices,
183 cases of endophthalmitis were reported
after 503,890 IVIs (incidence of 0.036%) [22].
Taken together, endophthalmitis rates seem
higher for office-based settings. Abell et al. from
Australia were able to compare the risk of
endophthalmitis after performing IVIs in an
operating theater versus an office in the same
center, and they found that endophthalmitis
rates were significantly lower in the operating
theaters [operating theater: 0 cases in 8,873
(0%); office: 4 cases in 3376 IVIs (0.12%);
P = 0.006] [23]. Dossorps et al. retrospectively
investigated factors influencing the incidence of
endophthalmitis in 25 French centers [65 cases
in 316,576 IVIs (0.021%)] and found a border-
line-significant trend towards a lower risk of
endophthalmitis in settings with filtration
airflow when compared with settings without
filtration airflow (P = 0.079) [24]. Bande et al.
systematically reviewed studies investigating
the incidence of endophthalmitis after IVIs and
performed a meta-regression which indicated
that there was no significant difference in
endophthalmitis incidence after IVIs were per-
formed in operating theaters versus an office-
based setting [25]. In conclusion, determining a
gold standard for the setting to use for IVI is
difficult. Randomized clinical trials are needed
to before any firm conclusions can be drawn
about the superiority or noninferiority of one
setting compared to the other. Patients with
incident endophthalmitis after an IVI may be at
an increased risk of developing endophthalmitis
again after IVI in the future. If these patients
change clinic after the endophthalmitis, a ret-
rospective study conducted at that clinic may
show an incorrectly low incidence of endoph-
thalmitis. Thus, prospective controlled clinical
studies are needed. Looking at the clinical evi-
dence available so far, it is important to realize
that the risk of endophthalmitis after IVIs—re-
gardless of the setting—is very low. Addition-
ally, when asked, patients do not seem to have
any clear pattern of preference for the operating
theater or office [26].
Who Should Perform the Injection?
Around the world, regulations and traditions
strongly influence who performs the injection.
While some centers allocate consultant oph-
thalmologists or only allow vitreoretinal sur-
geons to perform the injection, others allocate
this task to residents. Because of the increasing
demand for this procedure, its simplicity, and
the generally low prevalence of complications,
some centers have employed nurses to perform
the IVIs [27]. Experiences so far from centers in
Denmark [28, 29], the UK [30], Norway [31],
and New Zealand [32] suggest that this is feasi-
ble (in terms of training, implementation,
capacity improvements, and patient satisfac-
tion) and safe (in terms of complication rates
compared with IVIs given by physicians)
[27, 29, 31].
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Use of Injection-Assisting Devices
A number of IVI-assisting devices exist [33],
among which the InVitria Injection Assistant
(FCI Ophthalmics, Paris, France) is one of the
more widely used. The use of such devices
ensures that the desired distance from the lim-
bus is achieved, and may facilitate a faster pro-
cedure with fewer steps. The incidence of
endophthalmitis after IVI in which an assisting
device was used is yet to be documented.
Optimizing Patient Comfort
Preparations can be made to optimize patient
comfort. Patients receiving an IVI for the first
time should be allocated more time to learn
about the injection and monitored for unex-
pected reactions. Gomez et al. studied patient
comfort during IVIs and found that favorable
strategies were the presence of an extra staff
member during the injection, the use of a neck
pillow, and the provision of a verbal warning
prior to the IVI [34]. When bilateral IVIs were
necessary, the majority of the patients preferred
to have them performed on the same day [34].
In addition, patients between 30 and 60 years of
age preferred to have their hand held during the
IVI and to have background music playing
during the injection [34]. Music is played in
operating theaters in many surgical specialties.
Specifically for IVIs, Chen et al. documented
that classical music in the waiting room and in
the operating theater led to decreased anxiety
and increased patient satisfaction [35]. How-
ever, classical music did not influence pain
perception [35]. Irrigating the eye after the IVI
leads to less epithelial staining but has no
impact on redness, lacrimation, or the sensation
of pain, burning, or grittiness [36]. In line with
this, several centers apply lubricant drops after
the IVI to help reduce the sensation of pain and
grittiness and thus further improve patient
comfort. After performing the IVI, it is recom-
mended that any information regarding the
patient’s specific reaction to any part of the
protocol should be noted, as should adjust-
ments made to the protocol. This approach can
allow a certain degree of individualization, fur-
ther optimizing patient comfort.
Since patients follow a regimen involving
multiple IVIs, patients receiving IVIs often visit
the clinic several times per year. Organizing an
IVI service may lead to less time spent at the
clinic or hospital [37], which is important from
a patient perspective since the perceived burden
of treatment may influence the adherence to
therapy. One example of organizing an IVI ser-
vice that reduces the time spent on the patient
is to arrange for the retinal assessment and IVI
to be performed on the same day [37]. In a
Danish study of patients with neovascular age-
related macular degeneration who were aged
90 years or more and were predominantly resi-
dent in rural areas of Denmark, approximately
15% of the patients discontinued treatment
because the patients’ perceived burden of
treatment was too high [16].
PATIENT
Contraindications
Hypersensitivity
If the patient is known to have hypersensitivity
reactions towards the drug or any of the sub-
stances in the drug solution, IVI administration
is contraindicated.
Preexisting Ocular Conditions
• IVI therapy is contraindicated in patients
with any ocular or periocular infection at the
time of the IVI [38]. Infections must be
treated and followed by a new assessment
prior to IVI.
• IVI is not contraindicated in eyes with prior
intraocular or periocular surgery [38]. How-
ever, caution is advised for eyes with prior
glaucoma surgery such as trabeculectomy or
a drainage device to avoid injection at the
site of the filtering bleb or shunt. Some
evidence suggests that pharmacokinetic
properties may be different in previously
vitrectomized eyes, with a shorter half-life of
the anti-VEGF drug [38], which is no con-
traindication for IVI but may influence the
frequency of IVIs needed.
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• In patients with glaucoma, several studies
have documented a rise in the intraocular
pressure (IOP) after IVIs. Although the rise in
IOP may be slightly higher in eyes with
glaucoma, the IOP elevation is rarely alarm-
ingly high [39]. Rare cases with an unaccept-
able IOP elevation after IVI can be managed
[40].
• In cases with a history of previously unac-
ceptable IOP elevation after IVI, lowering the
IOP prior to the IVI should be considered.
Preexisting Medical Conditions
• Infections elsewhere and any fever in general
should prompt caution, as there may be a
risk of introducing systemically circulating
microorganisms through IVIs. Whether IVI
can be performed should be considered on a
case-by-case basis and by discussing the risks
with the patient. There is no clinical evi-
dence in this regard, so this is more of a
theoretical consideration.
• Since anti-VEGF administered through IVIs
can be detected systemically [41], there have
been debates regarding its use in patients
with recent cardiovascular or cerebrovascu-
lar events as to whether it could worsen a
potentially life-threatening condition
[42, 43]. Studies do not prove that IVIs with
anti-VEGF increase the risk of cardiovascular
or cerebrovascular events [42, 43]. In a
systematic review and meta-analysis, Rei-
baldi et al. did not find any strong evidence
suggesting a relationship between IVI with
anti-VEGF and increased mortality [44]. In
an interesting study of published systematic
reviews and meta-analyses on systemic
adverse events after IVI with anti-VEGF,
Thulliez et al. showed that different meta-
analyses found different signals, i.e., some
studies found an association with an
increased risk of cardiovascular events
whereas others did not [45]. One important
perspective is that only patients identified as
being at high risk of a future cardiovascular
event prior to anti-VEGF therapy may have
an increased risk of developing a cardiovas-
cular event after the commencement of anti-
VEGF therapy [46]. Hence, from a practical
perspective, caution is advised in cases with
a recent vascular event [47] and, if possible,
the IVI should be postponed
until C 3 months after the vascular event.
In severely vision-threatened cases involving
patients with a recent vascular event, the use
of an anti-VEGF agent with a shorter half-life
should be considered, e.g., ranibizumab
instead of aflibercept.
• There are no known drug interactions with
IVI-administered anti-VEGF. Anticoagulants
do not increase the risk of complications
after IVIs [48, 49].
Pregnancy and Postpartum
Angiogenesis plays a major role in the devel-
opment of the placenta and the fetus. There is
limited evidence on the use of intravitreal anti-
VEGF in pregnancy, and the available literature
can mostly be categorized as low-grade evidence
(case reports, case series, expert recommenda-
tions) [50]. Since anti-VEGF administered
through IVIs can be detected systemically, there
is an important reason for caution. In rats, ter-
atogenic effects of IVI with anti-VEGF peak
during the first trimester [51]. Case reports of
IVI with anti-VEGF in the first trimester show
that 4 out of 13 cases resulted in fetal demise or
a complicated birth [50]. No sequelae were
reported for the 7 patients who received IVI
with anti-VEGF during the second or third tri-
mester. However, it is difficult to extrapolate
these few cases to decisions in real life. McFar-
land et al. investigated breast milk levels of anti-
VEGF after IVI therapy with bevacizumab and
did not find detectable levels with a threshold
level of 3 ng/mL [52]. Taken together, there are
reasons to avoid IVI therapy using anti-VEGF
during pregnancy, whereas possible side effects
of this therapy during the postpartum period
are more unclear. In some cases, steroid-based
IVIs or laser-based therapy are feasible substi-
tutes due to their better documented and tol-
erated safety profiles [53].
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Bilateral Injections
Same-day bilateral injections have been debated
due to concerns regarding an increased risk of
local and systemic complications [54]. However,
from the patient’s point of view, treatment of
bilateral disease on different days may increase
the perceived burden of treatment [34]. Studies
have investigated the safety profile of same-day
bilateral injections and found that rates of
endophthalmitis and systemic vascular events
were comparable to those for unilateral injec-
tions [54]. It is recommended that each injec-
tion should be considered a separate procedure.
Separate instruments and medication vials
should be used for each eye to decrease the risk
of potential bilateral contamination.
PROPOSED PROCEDURE
The proposed procedure for anti-VEGF IVI is
descibed in Table 1. Various aspects of the pro-
cedure are discussed in more detail below.
Face Masks, Gloves, and Drapes
Studies of post-IVI acquired endophthalmitis
show that the most commonly cultured bacteria
are Staphylococcus species followed by Strepto-
coccus species [55]. Staphylococci may reside in
conjunctival membranes and are often part of
the flora of the patient [56], whereas strepto-
cocci reside in the oronasal cavities and the
upper respiratory system but are uncommon in
the conjunctival membranes [56]. Therefore, it
is logical to minimize the aerosolization of
oropharyngeal droplets by using face masks
during the procedure.
Hand hygiene and the use of gloves are a
fundamental practice in medicine, and World
Health Organization guidelines state that hand
hygiene and surgical gloves are required for all
surgical interventions [57]. Nevertheless,
according to a survey of retinal specialists in the
United States, clinical practices vary: 54% used a
single or double pair of gloves whereas 46%
used no gloves [56]. One retrospective study in a
center where no gloves were used reported an
endophthalmitis rate after office-based anti-
VEGF IVI of 9 cases in 15,895 (0.057%) [58],
which is similar to office-based incidence rates
reported elsewhere.
The EURETINA Expert Consensus Statement
recommends the use of face masks and gloves
[38]. There is no evidence or theoretical ratio-
nale for using a sterile drape. Drapes are also
considered optional in the EURETINA Expert
Consensus Statement [38].
Topical Anesthesia
There is no gold standard for the choice of
topical anesthesia. Shiroma et al. systematically
reviewed studies on topical anesthesia prior to
IVI and the patient pain experience and found
it to be generally mild regardless of the anes-
thetic employed [59]. Studies reviewed included
proparacaine, tetracaine, cocaine, lidocaine
pledget or gel, and subconjunctival injection of
2% lidocaine or 0.75% levobupivacaine [59].
The authors found that among these interven-
tions, subconjunctival injection of 2% lidocaine
may provide the greatest pain reduction [59].
However, considering that another noninvasive
topical anesthesia often suffices, the subcon-
junctival injection of 2% lidocaine should only
be considered in select cases where other
options provide insufficient anesthesia. Con-
sidering the number of IVI treatments and
treatment intervals, general anesthesia is not a
feasible option and should only be considered
for the very rare cases where topical anesthesia
cannot be used under any circumstances, e.g.,
in cases of severe manifest syringe phobia.
Topical Disinfection
Povidone-iodine is considered the gold standard
for preoperative surface preparation because of
its microbicidal properties and fast preparation
time [38]. The povidone-iodine concentration
plays a role in its disinfectant effects. Friedman
et al. investigated the contact time of 5% povi-
done-iodine in conjunctiva and the number of
colony-forming units upon sampling and cul-
turing [60]. The number of colony-forming
units did not decrease significantly at 15 s but
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Table 1 Proposed procedure for intravitreal injections
1. Prepare setting Operating theater with laminar air flow and a dental chair for the patient. The
chair can help the elderly patient move from a sitting to a supine position for
the injection, and then from a supine to a sitting position afterwards. All
rooms have two members of the medical staff on hand for the injection,
music available, and neck pillows. Medical staff use face masks and gloves for
all sterile procedures
2. Ensure patient identification, consent,
and eligibility
Talk with the patient to ensure identification and to discuss any
contraindications, allergies, and consent, as well as to confirm eye laterality
for treatment and the treatment drug
3. Prepare medication Prepare the relevant drug under sterile conditions using a large 27-gauge needle
and then change the needle used to a smaller 30-gauge needle. For prefilled
syringes, simply prepare the 30-gauge needle. Remove dead space and ensure
that there is only 0.05 mL of the drug in the syringe
4. Apply topical anesthesia Apply topical tetracaine twice, with a 60-s interval between applications
5. Apply topical disinfection Apply topical disinfectant once to conjunctiva, lids, and lashes and then wait
for 30 s
6. Lid speculum Insert a sterile lid speculum
7. Mark injection location Mark the location corresponding to the pars plana in the superotemporal
quadrant. Mark a distance to the limbus of 3.5 mm for pseudophakic eyes
and 4.0 mm for phakic eyes
8. Coordinate gaze direction Ask the patient to look in the direction opposite to the injection. For example,
when injecting into the superotemporal quadrant of the right eye, ask the
patient to look downwards and to the left
9. Hold the prepared syringe and a Q-tip Hold the prepared syringe in the dominant hand and a sterile Q-tip in the
nondominant hand
10. Place the Q-tip Place the Q-tip close to the area of injection and displace the conjunctiva
slightly
11. Insert the syringe Insert the syringe perpendicularly at the marked area of insertion in one
smooth motion. Insert the short 30-gauge needle about 1/2 of its length,
ensuring that it extends beyond the subretinal space and into the vitreous.
Inject the medicine slowly and remove the syringe
12. Remove lid speculum and consider
irrigation and/or lubricant
Remove the lid speculum. Consider irrigation and/or lubricant drops
13. Review alarm signs with the patient The patient should expect slight discomfort during the day of the intravitreal
injection, but significant pain, redness, or acute vision loss should prompt
contact with emergency eyecare
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did after 30 s and beyond. In line with these
findings, concentrations of povidone-iodine of
between 2.5% and 10% applied for 30–120 s
produce a sufficient bacteriocidal effect that
lasts throughout the entire IVI procedure [38].
Povidone-iodine for conjunctival administra-
tion is typically given at a 5% concentration,
and it should be administered upon the con-
junctiva. It should be noted that the preferred
concentration of povidone-iodine for use on
skin is higher, typically 10%. Chlorhexidine
0.1% can be used for patients with unaccept-
able irritation or hypersensitivity towards povi-
done-iodine, but requires a contact time of
5 min or longer to exert its full bacteriocidal
effects on Staphylococcus aureus and Escherichia
coli, and provides a narrower antimicrobial
spectrum than povidone-iodine [38].
Topical Antibiotics
Theoretically, the use of topical antibiotics
should decrease the bacterial load, but clinical
evidence does not show any clear benefit of
using topical antibiotics in conjunction with
IVIs [61]. Indeed, since IVIs are given multiple
times in the same eye, repeated exposure to
topical antibiotics is thought to promote the
development of resistant bacterial cultures and
to, paradoxically, lead to an increased incidence
of post-IVI endophthalmitis [62, 63]. Hence,
topical antibiotics are recommended neither
prior to nor after an IVI.
Needle Type
The appropriate needle gauge to use for IVI
should theoretically range between 27 and 33. It
is important to minimize structural damage in
order to avoid vitreous incarceration or reflux of
the medicine [38]. Several randomized clinical
trials have explored the relationship between
needle gauge, pain experience, and post-IVI IOP
[64–66]. The use of a smaller needle may reduce
the pain experienced by the patient, but the
difference is not clinically significant. Smaller
needle sizes are also associated with a larger rise
in IOP after IVI, although this temporary rise in
IOP is small and not of clinical significance. The
force required to penetrate the sclera with a
27-gauge needle is almost double that required
with a 30-gauge needle [67]. Thus, for practical
purposes, smaller needle sizes are preferred. The
EURETINA Expert Consensus Statement rec-
ommends a 30-gauge or thinner needle of
length 13–18 mm [38].
Lid Speculum
The use of a lid speculum or lid retractor can
help to avoid involuntary lid closure and con-
tact between the injection needle and lids or
lashes. Clinical evidence suggests that not using
a sterile lid speculum increases the risk of post-
IVI endophthalmitis [68]. Therefore, a sterile lid
speculum is recommended.
Injection
The injection is given through the pars plana of
the retina, 3.5 or 4 mm from the limbus
depending on whether the eye is pseudophakic
or phakic, respectively. The injection can theo-
retically be safely administered in all quadrants,
but is often given at the supero- or inferotem-
poral quadrant. It is given perpendicular to the
eye surface, which allows the medicine to be
administered into the vitreous. Injecting more
anteriorly to the pars plana increases the risk of
ciliary body hemorrhage or traumatic cataract,
while injecting more posteriorly increases the
risk of retinal detachment. Since many patients
undergo repeated IVIs, injection at the exact
same site should be avoided.
INFORMATION
Informed Consent Prior to Therapy
The patient should be informed about the nat-
ure of the disease, the rationale for treatment,
the treatment regimen (the number of and the
intervals between the injections and follow-up
visits), the potential complications, and the
prognosis. Patient information leaflets may be
used to provide this information. Unfortu-
nately, many patients do not remain well
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informed even when they have previously
signed an informed consent form. A Danish
study found that the majority of patients
receiving anti-VEGF have poor health literacy
levels [69]. A German study found that, among
patients receiving anti-VEGF, 64% expected an
improvement in visual acuity after the IVI, 42%
did not know what was given in the IVI, and
69% did not know about the risk of endoph-
thalmitis [70].
Alarm Signs After Therapy
The patient should be aware of common post-
IVI complications (discomfort, pain, and sub-
conjunctival hemorrhage), as well as uncom-
mon but important post-IVI complications:
traumatic cataract in\ 0.1% [27], retinal tear or
detachment in\ 0.1% [27], severe IOP eleva-
tion (rarely), vitreous hemorrhage (rarely), and
endophthalmitis in\0.02%. The patient
should expect slight discomfort during the day
of the IVI, but significant pain, redness, or acute
vision loss should prompt contact with emer-
gency eyecare, as they may be signs of impor-
tant complications that require timely
management, such as endophthalmitis, severe
IOP elevation, or retinal tear/detachment.
Information to be provided to the patient
regarding complications is listed in Table 2.
After IVI therapy, IOP measurements are per-
formed in some clinics on either a regular basis
or for select patients (e.g., those with glaucoma
or a previous acute increase in IOP). In some
clinics, counting fingers after IVI therapy is used
as a simple way to check for the presence of
severe IOP elevation and vision loss due to
retinal artery occlusion.
What Should Be Avoided After
the Injection?
There is no clinical evidence on what to avoid;
however, from a theoretical point of view,
attempts should be made to avoid a high load of
microorganisms at the area of injection
Table 2 Information to be provided to the patient regarding complications after intravitreal injection therapy with anti-
vascular endothelial growth factor
Common
Discomfort and pain Foreign body sensation and mild ocular discomfort is not unusual, especially as the topical
anesthetics wear off
Subconjunctival
hemorrhage
Subconjunctival hemorrhage can look dramatic, but is common and harmless
Uncommon
Traumatic cataract Needle-induced damage to the lens during an intravitreal injection can lead to a traumatic
cataract. This occurs in less than 1 out of 1000 injections
Retinal tear or detachment The procedure may facilitate a tear or detach the retina. This occurs in less than 1 out of 1000
injections
Severe intraocular pressure
elevation
The pressure in the eye may increase after an injection. In rare cases, this increase may require
medical attention and intervention
Vitreous hemorrhage In rare cases, a vitreous hemorrhage may occur after an injection
Endophthalmitis Severe pain, red eye, and blurry vision can be a sign of infection in the eye, which should
prompt the patient to seek emergency eyecare. This occurs in less than 1 out of 5000
injections
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immediately after the IVI. Because of this, we
recommend avoiding the following activities
for 24 h after the IVI: rubbing eyes, swimming,
gardening, wearing eye makeup, or performing
dusty work. Ongoing treatment with eye drops
can continue, but a new bottle should be
opened after the IVI.
CONCLUSION
IVI with anti-VEGF is an important, high-vol-
ume procedure for any ophthalmic service. In
this paper, we have provided a practical
approach to this procedure and considered
various aspects of the procedure, including the
setting, the patient, the procedure, and infor-
mation provided to the patient. In addition, we
have outlined our own protocol for treatment
that addresses these considerations. From a
procedural perspective, it is important to
understand that there is clinical evidence (albeit
not level 1 evidence) for some, but far from all,
of what we practice regarding IVI.
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1. Ohm J. Über die Behandlung der Netzhautablösung
durch operative Entleerung der subretinalen Flüs-
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6. Cehofski LJ, Honoré B, Vorum H. A review: pro-
teomics in retinal artery occlusion, retinal vein
occlusion, diabetic retinopathy and acquired mac-
ular disorders. Int J Mol Sci. 2017;18:E907.
7. Williams GA. IVT injections: health policy impli-
cations. Rev Ophthalmol. https://www.
reviewofophthalmology.com/article/ivt-injections-
health-policy-implications. Accessed 26 Nov 2019.
8. Hollingworth W, Jones T, Reeves BC, Peto T. A
longitudinal study to assess the frequency and cost
of antivascular endothelial therapy, and inequali-
ties in access, in England between 2005 and 2015.
BMJ Open. 2017;7:e018289.
200 Ophthalmol Ther (2020) 9:191–203
9. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X,
Klein R, Boyle JP. Projection of diabetic retinopathy
and other major eye diseases among people with
diabetes mellitus: United States, 2005–2050. Arch
Ophthalmol. 2008;126:1740–7.
10. Ansah JP, Koh V, de Korne DF, et al. Projection of
eye disease burden in Singapore. Ann Acad Med
Singapore. 2018;47:13–28.
11. Sedeh FB, Scott DAR, Subhi Y, Sørensen TL. Preva-
lence of neovascular age-related macular degenera-
tion and geographic atrophy in Denmark. Dan Med
J. 2017;64:A5422.
12. Stockwell RE, Ballard EL, O’Rourke P, Knibbs LD,
Morawska L, Bell SC. Indoor hospital air and the
impact of ventilation on bioaerosols: a systematic
review. J Hosp Infect. 2019;103:175–84.
13. Michels S, Becker M, Wachtlin J, Binder S. The
intravitreal injection: variations in regulations, cost
and reimbursement in Europe. Spektrum Augen-
heilkd. 2012;26:2.
14. National Society of Italian Ophthalmologists. Drug
IVI guidelines. https://www.sedesoi.com/pdf/
LINEE%20di%20indirizzo%20INTRAVITREALI%20_
aggiornate%20marzo%202017%20.pdf. Accessed 6
Jan 2020.
15. Samia-Aly E, Cassels-Brown A, Morris DS, Stancliffe
R, Somner JE. A survey of UK practice patterns in
the delivery of intravitreal injections. Ophthalmic
Physiol Opt. 2015;35:450–4.
16. Subhi Y, Sørensen TL. Neovascular age-related
macular degeneration in the very old (C 90 years):
epidemiology, adherence to treatment, and com-
parison of efficacy. J Ophthalmol. 2017;2017:
7194927.
17. Casparis H, Wolfensberger TJ, Becker M, et al.
Incidence of presumed endophthalmitis after
intravitreal injection performed in the operating
room: a retrospective multicenter study. Retina.
2014;34:12–7.
18. Brynskov T, Kemp H, Sørensen TL. No cases of
endophthalmitis after 20,293 intravitreal injections
in an operating room setting. Retina. 2014;34:
951–7.
19. Freiberg FJ, Brynskov T, Munk MR, et al. Low
endophthalmitis rates after intravitreal anti-vascu-
lar endothelial growth factor injections in an
operation room: a retrospective multicenter study.
Retina. 2017;37:2341–6.
20. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis
associated with intravitreal anti-vascular
endothelial growth factor therapy injections in an
office setting. Am J Ophthalmol. 2008;145:879–82.
21. Meredith TA, McCannel CA, Barr C, et al. Postin-
jection endophthalmitis in the comparison of age-
related macular degeneration treatments trials
(CATT). Ophthalmology. 2015;122:817–21.
22. Rayess N, Rahimy E, Storey P, et al. Postinjection
endophthalmitis rates and characteristics following
intravitreal bevacizumab, ranibizumab, and
aflibercept. Am J Ophthalmol. 2016;165:88–93.
23. Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal
injections: is there benefit for a theatre setting? Br J
Ophthalmol. 2012;96:1474–8.
24. Dossarps D, Bron AM, Koehrer P, Aho-Glélé LS,
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